{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:25:44Z","timestamp":1785245144287,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jaut.2012.08.002","type":"journal-article","created":{"date-parts":[[2012,9,11]],"date-time":"2012-09-11T19:46:53Z","timestamp":1347392813000},"page":"74-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction"],"prefix":"10.1016","volume":"40","author":[{"given":"Unni Krishna S.R.L.","family":"Samavedam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Kalies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengameh","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yask","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel F.","family":"Jonkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rose-John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2012.08.002_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2012.08.002_bib2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1146\/annurev.immunol.15.1.797","article-title":"Gp130 and the interleukin-6 family of cytokines","volume":"15","author":"Taga","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaut.2012.08.002_bib3","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.4049\/jimmunol.172.9.5676","article-title":"Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms","volume":"172","author":"McLoughlin","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2012.08.002_bib4","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.4049\/jimmunol.148.7.2175","article-title":"Human soluble IL-6 receptor: its detection and enhanced release by HIV infection","volume":"148","author":"Honda","year":"1992","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2012.08.002_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1074-7613(04)00003-2","article-title":"IL-6 trans-signaling: the heat is on","volume":"20","author":"Rose-John","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2012.08.002_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1074-7613(01)00151-0","article-title":"Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation","volume":"14","author":"Hurst","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2012.08.002_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/368339a0","article-title":"Impaired immune and acute-phase responses in interleukin-6-deficient mice","volume":"368","author":"Kopf","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2012.08.002_bib8","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2009-12-259457","article-title":"Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow","volume":"116","author":"Winter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2012.08.002_bib9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1084\/jem.180.4.1243","article-title":"Defective inflammatory response in interleukin 6-deficient mice","volume":"180","author":"Fattori","year":"1994","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaut.2012.08.002_bib10","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.1780310614","article-title":"Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides","volume":"31","author":"Houssiau","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2012.08.002_bib11","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/gut.32.12.1531","article-title":"High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis","volume":"32","author":"Mahida","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.jaut.2012.08.002_bib12","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1164\/ajrccm.151.5.7735584","article-title":"Circulating interleukin-6 levels in patients with bronchial asthma","volume":"151","author":"Yokoyama","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaut.2012.08.002_bib13","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaut.2012.08.002_bib14","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2012.08.002_bib15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1161\/01.CIR.0000043802.38699.66","article-title":"Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3","volume":"107","author":"Eriksson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jaut.2012.08.002_bib16","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1073\/pnas.95.14.8222","article-title":"Interleukin 6 plays a key role in the development of antigen-induced arthritis","volume":"95","author":"Ohshima","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaut.2012.08.002_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.187.4.461","article-title":"Interleukin 6 is required for the development of collagen-induced arthritis","volume":"187","author":"Alonzi","year":"1998","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaut.2012.08.002_bib18","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.4049\/jimmunol.161.12.6480","article-title":"IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells","volume":"161","author":"Samoilova","year":"1998","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2012.08.002_bib19","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4049\/jimmunol.169.2.1077","article-title":"Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production","volume":"169","author":"Deng","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2012.08.002_bib20","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jaut.2012.08.002_bib21","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.4049\/jimmunol.171.6.3202","article-title":"Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130","volume":"171","author":"Nowell","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2012.08.002_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4049\/jimmunol.182.1.613","article-title":"Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis","volume":"182","author":"Nowell","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2012.08.002_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14728222.11.5.613","article-title":"The IL-6\/sIL-6R complex as a novel target for therapeutic approaches","volume":"11","author":"Rose-John","year":"2007","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaut.2012.08.002_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14728222.2012.660307","article-title":"Hitting a complex target: an update on interleukin-6 trans-signalling","volume":"16","author":"Waetzig","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaut.2012.08.002_bib25","doi-asserted-by":"crossref","first-page":"e6207","DOI":"10.1371\/journal.pone.0006207","article-title":"Lack of IL-6 during coxsackievirus infection heightens the early immune response resulting in increased severity of chronic autoimmune myocarditis","volume":"4","author":"Poffenberger","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jaut.2012.08.002_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI1368","article-title":"IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses","volume":"101","author":"Xing","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaut.2012.08.002_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaut.2012.08.002_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.V83.1.113.113","article-title":"Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55","volume":"83","author":"Tilg","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2012.08.002_bib29","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1210\/endo.142.11.8511","article-title":"Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis","volume":"142","author":"De Benedetti","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.jaut.2012.08.002_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1043-4666(03)00034-6","article-title":"Expression profiles of collagens, HSP47, TGF-beta1, MMPs and TIMPs in epidermolysis bullosa acquisita","volume":"21","author":"Razzaque","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.jaut.2012.08.002_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1590\/S0100-879X2007000500004","article-title":"TIMP-1 mediates the inhibitory effect of interleukin-6 on the proliferation of a hepatocarcinoma cell line in a STAT3-dependent manner","volume":"40","author":"Guo","year":"2007","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.jaut.2012.08.002_bib32","doi-asserted-by":"crossref","first-page":"13625","DOI":"10.1074\/jbc.273.22.13625","article-title":"Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity","volume":"273","author":"Silacci","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaut.2012.08.002_bib33","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/S0021-9258(18)52202-X","article-title":"Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1\/erythroid potentiating activity (TIMP-1\/EPA)","volume":"266","author":"Lotz","year":"1991","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaut.2012.08.002_bib34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1165\/rcmb.2008-0302OC","article-title":"IL-6 protects against hyperoxia-induced mitochondrial damage via Bcl-2-induced Bak interactions with mitofusions","volume":"41","author":"Waxman","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaut.2012.08.002_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2559.2005.02178.x","article-title":"IL-6, its receptors and its relationship with Bcl-2 and Bax proteins in infiltrating and in situ human breast carcinoma","volume":"47","author":"Garcia-Tu\u00f1\u00f3n","year":"2005","journal-title":"Histopathology"},{"key":"10.1016\/j.jaut.2012.08.002_bib36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF02507102","article-title":"Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid","volume":"288","author":"Schmidt","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaut.2012.08.002_bib37","first-page":"339","article-title":"Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?","volume":"144","author":"Ludwig","year":"2009","journal-title":"G\u00a0Ital Dermatol Venereol"},{"key":"10.1016\/j.jaut.2012.08.002_bib38","first-page":"220","volume":"13","author":"Ameglio","year":"1999","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"key":"10.1016\/j.jaut.2012.08.002_bib39","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1365-2133.1998.02169.x","article-title":"Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity","volume":"138","author":"Ameglio","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaut.2012.08.002_bib40","doi-asserted-by":"crossref","first-page":"875394","DOI":"10.1155\/2008\/875394","article-title":"Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris","volume":"2008","author":"Narbutt","year":"2008","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaut.2012.08.002_bib41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1523-1747.2000.00835.x","article-title":"In\u00a0vitro and in\u00a0vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis","volume":"114","author":"Feliciani","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaut.2012.08.002_bib42","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jaut.2012.08.002_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A\u00a0comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaut.2012.08.002_bib44","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A\u00a0comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaut.2012.08.002_bib45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI113373","article-title":"Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen","volume":"81","author":"Woodley","year":"1988","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaut.2012.08.002_bib46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.det.2011.03.003","article-title":"Pathogenesis of epidermolysis bullosa acquisita","volume":"29","author":"Ludwig","year":"2011","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaut.2012.08.002_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clindermatol.2011.03.011","article-title":"Epidermolysis bullosa acquisita","volume":"30","author":"Gupta","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaut.2012.08.002_bib48","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI200521386","article-title":"Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen","volume":"115","author":"Sitaru","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaut.2012.08.002_bib49","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/08916934.2011.606451","article-title":"Model systems duplicating epidermolysis bullosa acquisita: a methodological review","volume":"45","author":"Ludwig","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaut.2012.08.002_bib50","doi-asserted-by":"crossref","first-page":"27200","DOI":"10.1074\/jbc.M803694200","article-title":"Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130","volume":"283","author":"Tenhumberg","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaut.2012.08.002_bib51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/path.2857","article-title":"Autoantibody-induced intestinal inflammation and weight loss in experimental epidermolysis bullosa acquisita","volume":"224","author":"Ishii","year":"2011","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jaut.2012.08.002_bib52","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.0022-202X.2005.23912.x","article-title":"Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation","volume":"125","author":"Ludwig","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaut.2012.08.002_bib53","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/1529-0131(199908)42:8<1635::AID-ANR11>3.0.CO;2-Q","article-title":"Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice","volume":"42","author":"Sasai","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2012.08.002_bib54","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0192-0561(93)90061-3","article-title":"Enhanced expression of interleukin 6 in rat and murine arthritis models","volume":"15","author":"Sugita","year":"1993","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.jaut.2012.08.002_bib55","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/anr.1780320513","article-title":"Enhanced production of interleukin-6 in mice with type II collagen-induced arthritis","volume":"32","author":"Takai","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2012.08.002_bib56","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/0090-1229(89)90146-3","article-title":"Interleukin-6 in synovial fluid from patients with arthritis","volume":"50","author":"Waage","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jaut.2012.08.002_bib57","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2012.08.002_bib58","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.4049\/jimmunol.178.10.6514","article-title":"The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita","volume":"178","author":"Mihai","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2012.08.002_bib59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/path.2157","article-title":"NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage","volume":"212","author":"Chiriac","year":"2007","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jaut.2012.08.002_bib60","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/path.4023","article-title":"Genetic identification and functional validation of Fc\u03b3RIV as key molecule in autoantibody-induced tissue injury","volume":"228","author":"Kasperkiewicz","year":"2012","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jaut.2012.08.002_bib61","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1038\/jid.2010.230","article-title":"Fc\u03b3RIIA and Fc\u03b3RIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid","volume":"130","author":"Yu","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaut.2012.08.002_bib62","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/path.1674","article-title":"Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid","volume":"204","author":"Shimanovich","year":"2004","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jaut.2012.08.002_bib63","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","article-title":"Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer","volume":"19","author":"Lesina","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaut.2012.08.002_bib64","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.autrev.2009.01.011","article-title":"Apoptosis in pemphigus","volume":"8","author":"Schmidt","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2012.08.002_bib65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2011.02.003","article-title":"IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer","volume":"22","author":"Neurath","year":"2011","journal-title":"Cytokine Growth Factor Rev"}],"updated-by":[{"DOI":"10.1016\/j.jaut.2014.12.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000}}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841112001229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841112001229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:06:02Z","timestamp":1760256362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841112001229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":65,"alternative-id":["S0896841112001229"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2012.08.002","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2012.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}